Page 167 - Drug Class Review
P. 167
Drug Effectiveness Review Project
Drugs Authors and Year: Rockwood et al., 2001; 51 Markowitz et al., 2003 63 Country: Multinational Janssen Research Foundation To assess the efficacy and safety of GAL in AD Setting: Multi-center (43 centers in 6 countries) placebo galantamine N/A 24 – 32 mg/d 3 months 3 months 125 261 History of cognitive decline over the last 6 months; diagnosis of probable AD according to NINCDS/ADRDA; presence of mild to moderate dementia; MMSE of 11- 24; > 2 on ADAS-Cog; contact with a responsible caregiver Concomitant medical disease; other neurodegenerative disorder; previously
Alzheimer Study design: RCT Sample size: 386
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
